Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

scientific article published on 27 July 2020

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2020NatCo..11.3736C
P356DOI10.1038/S41467-020-17446-4
P698PubMed publication ID32719371

P50authorAbhishek N PrasadQ56338678
Kevin MelodyQ57079485
Heinz FeldmannQ60059378
Thomas W GeisbertQ60061444
Larry ZeitlinQ87766086
Krystle N AgansQ88870564
Armand SprecherQ92709196
Robert W CrossQ97905072
Joan B GeisbertQ109874939
Karla A. FentonQ109875099
P2093author name stringZachary A Bornholdt
Viktoriya Borisevich
Daniel J Deer
P2860cites workVesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesQ21131585
Effective post-exposure treatment of Ebola infectionQ21131616
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)Q28051937
Ebola and Marburg virus vaccinesQ30234637
Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques.Q33404944
Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trialQ33818337
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg virusesQ33987611
Reversion of advanced Ebola virus disease in nonhuman primates with ZMappQ34426585
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primatesQ34473079
EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strainQ34488551
Safety of recombinant VSV-Ebola virus vaccine vector in pigsQ35229679
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infectionQ35843254
Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus InfectionQ36043284
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virusQ36239796
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibodyQ39966889
Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus MakonaQ40093846
Two-mAb cocktail protects macaques against the Makona variant of Ebola virusQ40114600
mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptomsQ40231241
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infectionsQ44089771
Post-exposure treatments for Ebola and Marburg virus infectionsQ47548534
Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman PrimatesQ56766240
Role of the Ebola membrane in the protection conferred by the three-mAb cocktail MIL77Q59794597
Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid ProtectionQ64359231
A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman PrimatesQ64360457
New treatments for Ebola virus diseaseQ93160757
P433issue1
P921main subjectVSV-EBOVQ18085856
P304page(s)3736
P577publication date2020-07-27
P1433published inNature CommunicationsQ573880
P1476titlePrior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
P478volume11